G Protein-Coupled Receptors (GPCRs): Structure, Classification & Why They’re the Top Drug Targets
GPCRs sit at the center of modern pharmacology. Close to a third of all approved medicines work by switching these proteins on or off, yet a lot of students, and more than a few practicing clinicians, only ever meet them as a maze of numbered subtypes. This guide covers what GPCRs are, how they are built, how the field organizes them into families, and why they stay the most productive hunting ground in drug discovery.
What is a G protein-coupled receptor?
A G protein-coupled receptor, usually shortened to GPCR and sometimes called a 7TM receptor, is a membrane protein that sits in the outer envelope of a cell and passes signals from outside to inside. The “7TM” name comes from the receptor’s shape: one protein chain that weaves across the cell membrane seven times, forming seven hydrophobic transmembrane domains numbered TM1 through TM7.
Every GPCR shares the same basic layout. An extracellular N-terminus faces outside the cell. An intracellular C-terminus faces inside. The seven transmembrane helices are joined on the outside by three extracellular loops (ECL1 to ECL3) and on the inside by three intracellular loops (ICL1 to ICL3). The intracellular side is where the receptor meets its G protein partners, and that meeting is what turns an outside signal into a cellular response.
The human genome holds the instructions for about 800 GPCRs. Nearly half handle sensory work: some 400 detect odors, about 33 register tastes, 10 pick up light, and 5 sense pheromones. The other roughly 350 non-sensory GPCRs respond to messengers of every size, from small molecules and single ions to peptides and large proteins. These are the receptors behind most drugs people take, even though only a minority have been turned into medicines.
How GPCRs are classified
Two systems dominate the literature, and knowing both spares a lot of confusion when reading the research.
The older scheme, built on sequence similarity, divides GPCRs into six classes:
- Class A is the rhodopsin-like family, by far the largest
- Class B is the secretin receptor family
- Class C is the metabotropic glutamate family
- Class D covers fungal mating pheromone receptors
- Class E covers cyclic AMP receptors
- Class F covers the frizzled and smoothened receptors
Classes D and E show up in fungi and other organisms but not in vertebrates, so a vertebrate-centered view leans on a second scheme.
The second scheme, GRAFS, groups vertebrate GPCRs into five families whose names form the acronym:
- Glutamate family (Class C) includes the metabotropic glutamate receptors, the calcium-sensing receptor, and GABA-B receptors, plus some taste and pheromone receptors
- Rhodopsin family (Class A) is the broadest group, covering receptors for small molecules, neurotransmitters, peptides, and hormones, along with olfactory and visual receptors
- Adhesion family receptors carry unusually large extracellular N-termini that get cut loose from the 7TM core at a conserved site during maturation
- Frizzled family has the ten frizzled proteins and smoothened, switched on by WNT and Hedgehog signaling
- Secretin family is a compact set of 15 human genes whose ligands are polypeptide hormones such as glucagon, GLP-1, GIP, secretin, VIP, and PACAP
The GPCR families at a glance
Counting receptors by family shows where the field’s attention has landed. The table separates receptors with known natural ligands from orphans, whose endogenous messenger has not yet been pinned down, and from the sensory receptors that handle smell, sight, taste, and pheromone detection.
| Family | Class A | Class B (Secretin) | Class C (Glutamate) | Adhesion | Frizzled |
| Receptors with known ligands | 197 | 15 | 12 | 0 | 11 |
| Orphans | 87 (54) | – | 8 (1) | 33 (7) | 0 |
| Sensory (olfaction) | 390 | – | – | – | – |
| Sensory (vision) | 10 opsins | – | – | – | – |
| Sensory (taste) | 30 taste 2 | – | 3 taste 1 | – | – |
| Sensory (pheromone) | 5 vomeronasal 1 | – | – | – | – |
| Total | 719 | 15 | 23 | 33 | 11 |
Class A dwarfs the rest, which is why most drug-discovery effort flows toward rhodopsin-like receptors. The adhesion and frizzled families stand out for how many orphans they still hold.
Sensory and non-sensory roles
The sensory GPCRs deserve a moment because they explain the large counts above. Olfactory receptors alone account for about 390 Class A entries, and they are seven-transmembrane receptors in every structural sense. They usually stay out of pharmacological tables simply because nobody has assembled extensive ligand data for them. Vision relies on about 10 opsins, taste on some 30 bitter receptors plus 3 sweet/umami receptors, and a small set of vomeronasal receptors handles pheromone cues.
The non-sensory GPCRs are where medicine happens. These receptors mediate signaling by ligands of every size, and they are the targets behind most clinically used drugs. Serotonin receptors, adrenergic receptors, dopamine receptors, muscarinic acetylcholine receptors, opioid receptors, and histamine receptors all belong here.
Orphan receptors and pseudogenes
A large share of GPCRs are still orphans: proteins with a clear 7TM shape but no confirmed natural ligand. Some already have a proposed endogenous messenger from at least one publication, while many remain completely unpaired. The adhesion and Class A families carry the largest orphan pools, and those represent some of the most interesting untapped ground in the field.
The human genome also carries GPCR pseudogenes, stretches of DNA related to working receptors in other species such as rats and mice that no longer make a functional protein in people. Examples include GNRHR2, GPR79, HTR5BP, and a long list of taste receptor and trace amine-associated receptor pseudogenes. Tracking these matters because a gene that works in a lab animal may be silent in humans, a difference that can sink drug programs built on cross-species assumptions.
Major therapeutic subfamilies
A few GPCR groups earn individual mention because of how often they show up in the clinic.
Serotonin (5-HT) receptors. Apart from the ion-channel 5-HT3 subtype, the serotonin receptors are GPCRs activated by 5-hydroxytryptamine. They split into families such as 5-HT1, 5-HT2, 5-HT4, 5-HT6, and 5-HT7, and they sit behind treatments for depression, migraine, anxiety, and nausea. The 5-HT2A receptor draws attention because many antipsychotic drugs bind it.
Muscarinic acetylcholine receptors. Five subtypes, M1 through M5, respond to acetylcholine. M1, M3, and M5 prefer Gq/11 proteins, while M2 and M4 prefer Gi/o proteins. Approved muscarinic drugs run from pilocarpine for glaucoma to atropine for bradycardia and organophosphate poisoning, and newer agents aimed at single subtypes are moving into psychiatry.
Adrenoceptors, dopamine receptors, opioid receptors, and histamine receptors. Each family spans multiple subtypes with distinct tissue distributions and jobs, and each supports a wide roster of approved medicines, from beta-blockers and stimulants to painkillers and allergy treatments.
Metabotropic glutamate, calcium-sensing, GABA-B, and frizzled receptors. These Class C and Class F members show how GPCRs reach past classic neurotransmission into metabolism, bone regulation, and developmental pathways such as WNT signaling.
Why GPCRs dominate drug discovery
A few traits make GPCRs attractive targets. They sit on the cell surface, so a drug does not need to cross the membrane to reach them. An antibody or small molecule in the extracellular space can do the job. Their seven-helix pocket offers many angles for selective binding, which lets chemists design compounds that favor one subtype over another and dodge unwanted side effects. And because so many diseases trace back to faulty signaling, a receptor that misbehaves in one tissue often gives a clean point to intervene.
The trade-off is complexity. A single receptor can couple to more than one G protein, can be modified after translation, and can pair with other receptors to change its behavior. The 5-HT2C receptor, for example, yields several functional isoforms through RNA editing, which changes how strongly it couples to Gq/11. Those layers of regulation mean a drug’s real-world effects can drift from what a simple binding assay predicts.
Classification and nomenclature keep the field coherent
Past the science, GPCR research depends on consistent naming. Official classification and nomenclature, maintained with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology, give every receptor a stable identity. That consistency is what lets a pharmacologist in one lab trust data from another, and it underpins the curated reference tables drug hunters use when picking a target and choosing a selective tool compound.
The bottom line
G protein-coupled receptors are the largest class of membrane proteins in the human genome and the most heavily targeted family of drug targets in medicine. Their seven-helix structure is conserved across roughly 800 human receptors, but their functions run from smelling coffee to regulating heart rate, mood, and metabolism. The Class A-to-F and GRAFS systems give researchers a shared map of this vast territory, while orphan receptors and pseudogenes mark the frontiers still being explored. Anyone working in pharmacology, medicine, or drug development needs a working grasp of how GPCRs are built and organized, because almost every other topic in the field connects back to them.
